Biomatter raised USD 18 million in a Series A led by Astanor. The Vilnius company uses artificial intelligence and experimental biology to design enzymes for industrial customers. It says the capital will support international expansion, additional laboratory capacity and further development of its design platform. Technical performance and customer impact claims remain company reported. The amount, round, location and lead investor were confirmed through the company announcement and independent reporting by TNW. The financing is recorded in the currency used by the company announcement.
Biomatter raises USD 18m Series A for AI enzyme design
Astanor led the financing for the Lithuanian biotechnology company.

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


